Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Down 49.7% in 4 Weeks, Here's Why Coherus Oncology (CHRS) Looks Ripe for a Turnaround
Coherus Oncology: 3 Key Takeaways for Long-Term Investors
Coherus Oncology, Inc. (CHRS) Q3 2026 Earnings Call Transcript
What Coherus Oncology (CHRS) Said on Its Q3 Earnings Call
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates
Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan
Will Coherus Oncology (CHRS) Report Negative Earnings Next Week? What You Should Know
Coherus Oncology, Inc. (CHRS) Discusses Tagmokitug Interim Clinical Data in Esophageal Cancer Transcript
Coherus Oncology Reports 89% Response Rate in Early ESCC Study
Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development
Coherus to Participate in Upcoming Investor Conferences
Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
Comparing Coherus Oncology (NASDAQ:CHRS) and Molecular Partners (NASDAQ:MOLN)
Contrasting Emergent Biosolutions (NYSE:EBS) and Coherus Oncology (NASDAQ:CHRS)
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
Coherus Oncology, Inc. (CHRS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BlackRock Inc. Takes $16.80 Million Position in Coherus Oncology, Inc. $CHRS
Coherus to Participate in Upcoming Investor Conferences
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights